EPRX

Eupraxia Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

3.940

+0.070(+1.810%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

3.960

Open

3.8571

VWAP

3.82

Vol

17.44K

Mkt Cap

141.24M

Low

3.6669

Amount

66.59K

EV/EBITDA(TTM)

Total Shares

35.85M

138.64M

EV/OCF(TTM)

P/S(TTM)

Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.

2 Analyst Rating

204.58% Upside

Wall Street analysts forecast EPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EPRX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

204.58% Upside

Current: 3.940

Low

12.00

Averages

12.00

High

12.00

204.58% Upside

Current: 3.940

Low

12.00

Averages

12.00

High

12.00

Rodman & Renshaw

Brandon Folkes

Strong Buy

Initiates

2024-11-14

Reason

Rodman & Renshaw

Brandon Folkes

Price Target

2024-11-14

Initiates

Strong Buy

Reason

Rodman & Renshaw analyst Brandon Folkes initiated coverage of Eupraxia Pharmaceuticals with a Buy rating and $9 price target.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Eupraxia Pharmaceuticals Inc (EPRX.O) is -4.87, compared to its 5-year average forward P/E of -3.17. For a more detailed relative valuation and DCF analysis to assess Eupraxia Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.17

Current PE

-4.87

Overvalued PE

-0.56

Undervalued PE

-5.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.83

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.61

Undervalued EV/EBITDA

-5.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

FY2025Q1

YoY :

+6.75%

-6.71M

Operating Profit

FY2025Q1

YoY :

+9.91%

-6.77M

Net Income after Tax

FY2025Q1

YoY :

-9.52%

-0.19

EPS - Diluted

FY2025Q1

YoY :

+0.73%

-6.17M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

EPRX News & Events

Events Timeline

2025-05-06 (ET)

2025-05-06

18:02:15

Eupraxia Pharmaceuticals reports Q1 net loss $6.8M vs. $6.2M last year

2025-05-05 (ET)

2025-05-05

07:18:52

Eupraxia Pharmaceuticals announces treatment outcomes for EP-104GI

2025-03-20 (ET)

2025-03-20

17:40:41

Eupraxia Pharmaceuticals reports FY24 EPS (76c), consensus (63c)

News

1.0

05-07Yahoo Finance

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

9.5

05-06Newsfilter

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

9.0

05-05NASDAQ.COM

Eupraxia Pharma Reports Positive 9-month Data From RESOLVE Phase 1b/2a Study